Literature DB >> 8591620

Malignant insulinoma: permanent hepatic artery embolization of liver metastases--preliminary results.

F W Winkelbauer1, B Nierderle, O Graf, R Prokesch, S Thurnher, R Wildling, J Lammer.   

Abstract

PURPOSE: To evaluate permanent hepatic artery embolization of liver metastases of malignant insulinoma as a therapeutic procedure.
METHODS: Three female patients had persistent severe hypoglycemia after distal pancreatectomy because of a malignant insulinoma. Computed tomography (CT) and CT-portography (CTAP) were used for tumor assessment and follow-up and demonstrated multiple hypervascular metastases 0.5-3 cm in diameter in both lobes of the liver. Unilobar sequential transcatheter embolization of the hepatic artery was performed with an interval of 1-2 months between the procedures. Permanent occlusion was achieved by using a mixture of n-butyl-2-cyanoacrylate and ethiodized oil as an embolizing agent.
RESULTS: In all patients, embolization of the hepatic artery was technically feasible and complete occlusion could be obtained. In two patients, collaterals originating from the right inferior phrenic artery were embolized superselectively 3 months after bilobar embolization. CTAP at that time revealed marked decrease in tumor size of more than 50%. All patients responded to the treatment as confirmed by normalization of measurable hormone levels, glucose levels, and disappearance of symptoms. Two patients are still alive after 24 and 31 months from the time of the first embolization. Current investigations revealed normal laboratory data and no further tumor progression in the liver. The third patient died 15 months after the first embolization; she also had developed ileus due to local recurrence of the primary tumor and lymph node metastases.
CONCLUSION: Hepatic arterial embolization appears to be an effective means of palliation for liver metastases of malignant insulinoma. Long-term improvement seems most likely to be the result of extensive ischemia from permanent occlusion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8591620     DOI: 10.1007/bf00338301

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  24 in total

1.  Pancreatic islet cell tumors.

Authors:  T A Broughan; J D Leslie; J M Soto; R E Hermann
Journal:  Surgery       Date:  1986-06       Impact factor: 3.982

2.  Metastatic islet cell tumour with clinical manifestations of insulin and glucagon excess: successful treatment by hepatic artery embolization and chemotherapy.

Authors:  S M Lee; A Forbes; R Williams
Journal:  Eur J Surg Oncol       Date:  1988-06       Impact factor: 4.424

3.  Hemodynamic changes after transcatheter arterial embolization of hepatocellular carcinomas.

Authors:  P Taourel; M Dauzat; M Lafortune; J Pradel; M Rossi; J M Bruel
Journal:  Radiology       Date:  1994-04       Impact factor: 11.105

4.  Modification of cyanoacrylate for therapeutic embolization: preliminary experience.

Authors:  L D Cromwell; C W Kerber
Journal:  AJR Am J Roentgenol       Date:  1979-05       Impact factor: 3.959

5.  Bile duct scarring following ethanol embolization of the hepatic artery: an experimental study in monkeys.

Authors:  J L Doppman; M E Girton
Journal:  Radiology       Date:  1984-09       Impact factor: 11.105

6.  Stability studies on chemoembolization mixtures. Dialysis studies of doxorubicin and lipiodol with Avitene, Gelfoam, and Angiostat.

Authors:  D Struk; R N Rankin; S J Karlik
Journal:  Invest Radiol       Date:  1993-11       Impact factor: 6.016

7.  [Multi-visceral upper abdominal resection and orthotopic liver transplantation--a surgical treatment concept for regionally metastatic tumors of the endocrine pancreas].

Authors:  H J Wenisch; B H Markus; G H Herrmann; K H Usadel; A Encke
Journal:  Zentralbl Chir       Date:  1992       Impact factor: 0.942

8.  Determination of optimal time window for liver scanning with CT during arterial portography.

Authors:  O Graf; W I Dock; J Lammer; S Thurnher; K L Eibenberger; R Wildling; B Niederle; E K Lang; G Lechner
Journal:  Radiology       Date:  1994-01       Impact factor: 11.105

9.  Pancreatic insulinomas.

Authors:  F Menegaux; G Schmitt; M Mercadier; J P Chigot
Journal:  Am J Surg       Date:  1993-02       Impact factor: 2.565

10.  Proximal versus peripheral hepatic artery embolization experimental study in monkeys.

Authors:  J L Doppman; M Girton; R Kahn
Journal:  Radiology       Date:  1978-09       Impact factor: 11.105

View more
  5 in total

1.  Malignant metastatic insulinoma-postoperative treatment and follow-up.

Authors:  Achim Starke; Christiane Saddig; Lothar Mansfeld; Rainer Koester; Cyrus Tschahargane; Peter Czygan; Peter Goretzki
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

Review 2.  Malignant insulinoma: spectrum of unusual clinical features.

Authors:  Boaz Hirshberg; Craig Cochran; Monica C Skarulis; Steven K Libutti; H Richard Alexander; Bradford J Wood; Richard Chang; David E Kleiner; Phillip Gorden
Journal:  Cancer       Date:  2005-07-15       Impact factor: 6.860

Review 3.  The treatment of hyperinsulinemic hypoglycaemia in adults: an update.

Authors:  M V Davi; A Pia; V Guarnotta; G Pizza; A Colao; A Faggiano
Journal:  J Endocrinol Invest       Date:  2016-09-13       Impact factor: 4.256

4.  Guidelines for the use of NBCA in vascular embolization devised by the Committee of Practice Guidelines of the Japanese Society of Interventional Radiology (CGJSIR), 2012 edition.

Authors:  Yoshito Takeuchi; Hiroyuki Morishita; Yozo Sato; Shingo Hamaguchi; Noriaki Sakamoto; Hiroyuki Tokue; Takafumi Yonemitsu; Kenji Murakami; Hiroyasu Fujiwara; Keitaro Sofue; Toshi Abe; Hideyuki Higashihara; Yasuo Nakajima; Morio Sato
Journal:  Jpn J Radiol       Date:  2014-06-03       Impact factor: 2.374

5.  The importance of preoperative localisation procedures in organic hyperinsulinism--experience in 67 patients.

Authors:  Klaus Kaczirek; Ahmed Ba-Ssalamah; Wolfgang Schima; Bruno Niederle
Journal:  Wien Klin Wochenschr       Date:  2004-06-30       Impact factor: 1.704

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.